Literature DB >> 12027843

The sevoflurane saving capacity of a new anaesthetic agent conserving device compared with a low flow circle system.

M Enlund1, H Lambert, L Wiklund.   

Abstract

BACKGROUND: An anaesthetic agent conserving device (ACD) has been added to a Bain system to approach the agent-saving capacity of a low flow circle system.
METHODS: Randomly selected ASA physical status I patients received a standardized anaesthetic with sevoflurane in air/O2 through either a circle system with 1.5 l/min fresh gas flow (n = 8), or through a Bain system with an added ACD with fresh gas flow 4.4-6.4 l/min (n = 8). A target controlled infusion of remifentanil was used for analgesia.
RESULTS: The median sevoflurane consumption was 19.7 and 22.0 ml/MAC/h with the low flow circle system and the Bain system + ACD, respectively (P=0.10, Mann-Whitney U-test), or when adjusted for weight 0.25 and 0.28 ml/MAC/h/kg (P=0.26, Mann-Whitney U-test).
CONCLUSION: The expenditure of sevoflurane with a Bain system + ACD was close to that in a circle system with 1.5 l/min fresh gas flow. It is thereby possible to use sevoflurane to all its potential, performing for example rapid alterations in end-tidal concentration using high fresh gas flows by combining a Bain system with an ACD. Although the price is not decided for this not yet commercially available device, a potential for a lower cost exists. Additionally, there will be no concerns of toxic compounds produced in the absorber.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12027843     DOI: 10.1034/j.1399-6576.2002.460506.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  8 in total

1.  [Functioning of the anaesthetic conserving device: aspects to consider for use in inhalational sedation].

Authors:  A Meiser; M Bellgardt; H Vogelsang; C Sirtl; T Weber
Journal:  Anaesthesist       Date:  2010-11       Impact factor: 1.041

Review 2.  [New technical developments for inhaled sedation].

Authors:  A Meiser; H Bomberg; T Volk; H V Groesdonk
Journal:  Anaesthesist       Date:  2017-04       Impact factor: 1.041

3.  Long-term sedation in intensive care unit: a randomized comparison between inhaled sevoflurane and intravenous propofol or midazolam.

Authors:  Malcie Mesnil; Xavier Capdevila; Sophie Bringuier; Pierre-Olivier Trine; Yoan Falquet; Jonathan Charbit; Jean-Paul Roustan; Gerald Chanques; Samir Jaber
Journal:  Intensive Care Med       Date:  2011-03-29       Impact factor: 17.440

Review 4.  Efficient application of volatile anaesthetics: total rebreathing or specific reflection?

Authors:  Hagen Bomberg; Thomas Volk; Heinrich V Groesdonk; Andreas Meiser
Journal:  J Clin Monit Comput       Date:  2018-01-04       Impact factor: 2.502

5.  Technical performance and reflection capacity of the anaesthetic conserving device--a bench study with isoflurane and sevoflurane.

Authors:  Andreas Meiser; Martin Bellgardt; Javier Belda; Kerstin Röhm; Heinz Laubenthal; Clemens Sirtl
Journal:  J Clin Monit Comput       Date:  2009-02-03       Impact factor: 2.502

6.  Short-term sevoflurane sedation using the Anaesthetic Conserving Device after cardiothoracic surgery.

Authors:  Kerstin D Röhm; Michael W Wolf; Thilo Schöllhorn; Alexander Schellhaass; Joachim Boldt; Swen N Piper
Journal:  Intensive Care Med       Date:  2008-05-24       Impact factor: 17.440

7.  Anesthetic gas consumption with target-controlled administration versus a semi-closed circle system with automatic end-tidal concentration control in an artificial lung model.

Authors:  Martin Bellgardt; Vladimir Vinnikov; Adrian Iustin Georgevici; Livia Procopiuc; Thomas Peter Weber; Andreas Meiser; Jennifer Herzog-Niescery; Dominik Drees
Journal:  Med Gas Res       Date:  2022 Oct-Dec

Review 8.  A technical review of the history, development and performance of the anaesthetic conserving device "AnaConDa" for delivering volatile anaesthetic in intensive and post-operative critical care.

Authors:  Ron Farrell; Glen Oomen; Pauric Carey
Journal:  J Clin Monit Comput       Date:  2018-01-31       Impact factor: 2.502

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.